Value through Innovation25 May 2013
Boehringer Ingelheim Group of companies
In 2012, Boehringer Ingelheim's sales increased by 12 %.
Financial Highlights
| Boehringer Ingelheim group of companies |
2012 | 2011 |
Change |
|---|---|---|---|
|
Net sales |
14,691 | 13,171 |
12 % |
|
Net sales by region |
|
||
| Europe |
29 % | 31 % |
|
| Americas |
47 % | 46 % | |
| Asia, Australasia, Africa |
24 % | 23 % | |
|
Net sales by business area
|
|||
| Human Pharmaceuticals |
93 % | 93 % | |
| Animal Health |
7 % | 7 % | |
| Research and Development |
2,795 | 2,516 | 11 % |
| Personnel costs |
4,024 | 3,664 | 10 % |
| Average number of employees |
46,228 | 44,094 | 5 % |
| Operating income |
1,853 | 2,272 | -18 % |
| As % of net sales |
12,6 % | 17, 3 % | |
| Income after taxes |
1,237 | 1,476 | -16 % |
| As % of net sales |
8,4 % | 11,2 % | |
| Shareholders' equity |
6,178 | 7,466 | -17 % |
| Return on shareholders' equity |
16,6 % | 22,8 % | |
| Cash Flow |
2,225 | 2,378 | -6 % |
| Investments in tangible assets |
562 | 458 | 23 % |
| Depreciation of tangible assets |
793 | 535 | 48 % |
Amounts in millions of EUR, unless otherwise indicated
